This year could see the first trials of therapies employing base editing that introduce precise single-nucleotide changes into patient genomes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phage-assisted evolution of highly active cytosine base editors with enhanced selectivity and minimal sequence context preference
Nature Communications Open Access 24 February 2024
-
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity
Nature Biotechnology Open Access 10 November 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
07 June 2022
In the version of this article initially published, the quote in the second paragraph in Box 2 appeared without the contextual text “addressing the similar issue of foreign Cas9 protein,” which has now been amended.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Base editing marches on the clinic. Nat Biotechnol 40, 623–625 (2022). https://doi.org/10.1038/s41587-022-01326-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01326-x
